Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

Maria Gabriella Ferrandina; Manuela Ludovisi; Giacomo Corrado; Vito Carone; Vanda Salutari; Marco Petrillo; Giovanni Scambia

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

Maria Gabriella Ferrandina
, Manuela Ludovisi
, Giacomo Corrado
, Vito Carone
, Vanda Salutari
, Marco Petrillo
, Giovanni Scambia

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	187-193
Number of pages	7
Journal	Gynecologic Oncology
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CA125
Ovarian cancer
prognostic role
response to chemotherapy

Cite this

@article{1970295c85204ce0a3622019b20a57ac,

title = "Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.",

keywords = "CA125, Ovarian cancer, prognostic role, response to chemotherapy, CA125, Ovarian cancer, prognostic role, response to chemotherapy",

author = "Ferrandina, \{Maria Gabriella\} and Manuela Ludovisi and Giacomo Corrado and Vito Carone and Vanda Salutari and Marco Petrillo and Giovanni Scambia",

year = "2008",

language = "English",

pages = "187--193",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

}

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. / Ferrandina, Maria Gabriella; Ludovisi, Manuela; Corrado, Giacomo et al.
In: Gynecologic Oncology, 2008, p. 187-193.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

AU - Ferrandina, Maria Gabriella

AU - Ludovisi, Manuela

AU - Corrado, Giacomo

AU - Carone, Vito

AU - Salutari, Vanda

AU - Petrillo, Marco

AU - Scambia, Giovanni

PY - 2008

Y1 - 2008

KW - CA125

KW - Ovarian cancer

KW - prognostic role

KW - response to chemotherapy

KW - CA125

KW - Ovarian cancer

KW - prognostic role

KW - response to chemotherapy

UR - http://hdl.handle.net/10807/31923

M3 - Article

SN - 0090-8258

SP - 187

EP - 193

JO - Gynecologic Oncology

JF - Gynecologic Oncology

ER -

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

UN SDGs

Keywords

Other files and links

Cite this